India must upgrade its R&D

Drug development calls for colossal expenses. And even Big Pharma companies are facing a drought of blockbuster drugs. That, despite the fact that a firm like Pfizer spends up to $7.57 billion a year (around 7 times Ranbaxy’s annual turno ver, to put it in perspective) on R&D, which is around 14% of its sales. Financial Times Research Centre unveils that a new drug to market can now cost anything between $900 million and $1.2 billion.

For complete IIPM article click here

Source:- IIPM Editorial

Visit also:- IIPM Publication, Business & Economy & Arindam Chaudhuri Initiative